ImmunoCellular Therapeutics Ltd
OTC:IMUC

Watchlist Manager
ImmunoCellular Therapeutics Ltd Logo
ImmunoCellular Therapeutics Ltd
OTC:IMUC
Watchlist
Price: 0.194 USD
Market Cap: 14.2m USD

Net Margin
ImmunoCellular Therapeutics Ltd

0%
Current
0%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-5.9m
/
Revenue
0

Net Margin Across Competitors

No Stocks Found

ImmunoCellular Therapeutics Ltd
Glance View

Market Cap
14.2m USD
Industry
Biotechnology

ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company is headquartered in Westlake Village, California and currently employs 4 full-time employees. The company went IPO on 2006-09-19. The firm is developing immune-based therapies for the treatment of cancers. The firm's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. The company is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.

IMUC Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-5.9m
/
Revenue
0
What is the Net Margin of ImmunoCellular Therapeutics Ltd?

Based on ImmunoCellular Therapeutics Ltd's most recent financial statements, the company has Net Margin of 0%.

Back to Top